Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02220634 · ClinicalTrials.gov registry record · NA
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
A NA study, sponsored by National Jewish Health.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02220634: Clinical Trial NA study, sponsored by National Jewish Health.
NCT02220634 is a NA study that was terminated before completion, run by National Jewish Health. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02220634, a NA study, was terminated before completion, sponsored by National Jewish Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Regadenoson may offer improved ease of use, single dose administration, and better tolerance for testing for pulmonary hypertension than iNO. You will be screened to make sure Regadenoson is safe for you with a clinical evaluation, blood tests, and an ECG.
Interventions
- DRUG Regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-05-25 |
| Phase | NA |
Why NCT02220634 stopped before completion
NCT02220634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Regadenoson is the first listed.
NCT02220634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02220634 about?
NCT02220634 is a clinical study titled "Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension". The purpose of this study is to see if Regadenoson may offer improved ease of use, single dose administration, and better tolerance for testing for pulmonary hypertension than iNO. You will be screened to make sure Regadenoson is safe for you with a clinical evaluation, blood tests, and an ECG.
What is the current status of trial NCT02220634?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2014-08. Estimated completion is 2017-05-25.
What interventions are being tested in trial NCT02220634?
The interventions under investigation include: Regadenoson (DRUG).
Who is sponsoring clinical trial NCT02220634?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02220634's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia